We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Bring photo ID to vote Check what photo ID you'll need to vote in person in the General Election on 4 July.
As a precaution, companies are recalling some batches of irbesartan medicines due to presence of a chemical substance (AZBT) in an amount over the limit permitted for this product. Patients taking irbesartan medicines should continue to take their medication.
Specific batches of products supplied by the Marketing Authorisation Holders and parallel distributor companies are being recalled due to presence of a mutagenic impurity.
Specific batches of products supplied by Marketing Authorisation Holders and parallel distributor companies are being recalled due to presence of a mutagenic impurity.
Patients should not stop any treatments without consulting their doctor or pharmacist
Medreich PLC UK is recalling a batch of Mebeverine hydrochloride 135mg film-coated tablets as a precautionary measure due to out of specification results for tablet dissolution during routine product release testing.
Employment Tribunal decision.
Mirabegron is now contraindicated in patients with severe uncontrolled hypertension; advice about regular monitoring is being introduced because of cases of severe hypertension.
Contraindicated in patients with any known current cancer
Temporarily discontinue ibrutinib in patients who develop symptoms suggestive of ventricular arrhythmia and assess benefit-risk before restarting therapy. Establish hepatitis B virus status before initiating ibrutinib. Consider prophylaxis for patients who are at an increased risk of opportunistic infections.
Patients with cancer who received recombinant human erythropoietins in clinical trials had an increased risk of tumour progression and reduced overall survival compared with study controls.
Establish hepatitis B virus status before initiating daratumumab and in patients with unknown hepatitis B virus serology who are already being treated with daratumumab.
If bilirubin and/or creatinine test results are inconsistent with clinical observations, request re-testing using another method to determine the validity of the result.
The UK support to the Global Fund is helping to bring healthcare to the doorstep of rural Ethiopians through the training and deployment of health extension workers.
A letter was sent to healthcare professionals about mirabegron for symptomatic treatment of urgency, increased micturition frequency, or urgency incontinence.
The European Commission has published an amendment to the persistent organic pollutants regulation to include hexabromocyclododecane
The Government is making £500,000 available for new research into antibiotic-resistance bacteria, it was announced today. Following a report…
First published during the 2010 to 2015 Conservative and Liberal Democrat coalition government
A man and a woman who sold breast cancer and erectile dysfunction medicines illegally online appeared at Birmingham Crown Court.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).